Humana Inc. (NYSE:HUM – Get Free Report) announced a quarterly dividend on Wednesday, September 2nd. Stockholders of record on Friday, October 30th will be given a dividend of 0.885 per share by the insurance provider on Friday, November 27th. This represents a c) annualized dividend and a dividend yield of 0.9%. The ex-dividend date is Friday, October 30th.
Humana has raised its dividend payment by an average of 0.1%annually over the last three years. Humana has a payout ratio of 24.1% indicating that its dividend is sufficiently covered by earnings. Analysts expect Humana to earn $15.26 per share next year, which means the company should continue to be able to cover its $3.54 annual dividend with an expected future payout ratio of 23.2%.
Humana Trading Up 1.3%
Shares of HUM traded up $5.25 during trading hours on Wednesday, hitting $400.12. 1,138,234 shares of the stock were exchanged, compared to its average volume of 1,718,160. Humana has a fifty-two week low of $163.11 and a fifty-two week high of $428.88. The business has a 50-day moving average of $386.76 and a 200-day moving average of $292.15. The firm has a market capitalization of $48.05 billion, a P/E ratio of 37.85, a price-to-earnings-growth ratio of 2.18 and a beta of 0.72. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.74 and a quick ratio of 1.74.
Analyst Upgrades and Downgrades
A number of research analysts have recently issued reports on the company. Barclays boosted their price objective on Humana from $344.00 to $407.00 and gave the company an “equal weight” rating in a research note on Friday, July 31st. Morgan Stanley raised Humana from an “underweight” rating to an “equal weight” rating and raised their target price for the stock from $249.00 to $370.00 in a research note on Tuesday, August 4th. Oppenheimer reiterated an “outperform” rating and issued a $405.00 target price on shares of Humana in a report on Thursday, July 30th. Wolfe Research reissued an “outperform” rating and issued a $450.00 price target on shares of Humana in a research note on Monday, August 24th. Finally, Lake Street Capital began coverage on Humana in a report on Thursday, July 30th. They set a “buy” rating on the stock. Fourteen equities research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Humana has an average rating of “Hold” and a consensus price target of $403.91.
View Our Latest Stock Analysis on Humana
About Humana
Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.
In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.
Further Reading
- Five stocks we like better than Humana
- Striking Oil: How the U.S. Play for Venezuela Fuels Supermajors
- J.M. Smucker Stock’s Rally Has More Than Tariffs Behind It
- Wendy’s Rally Fades After Trian Steps Back: Was It Ever Real?
- GitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse Test
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.
